Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | EBMT 2018: Updates on advanced Hodgkin lymphoma treatment

Martin Hutchings • 19 Mar 2018
EBMT 2018
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Nivolumab Pembrolizumab

Treatment of advanced Hodgkin lymphoma has evolved dramatically in the last 10 years, especially with the introduction of PET-response adapted treatment and the introduction of novel agents. Martin Hutchings, MD, PhD from Copenhagen University Hospital, Copenhagen, Denmark discusses the latest advances and how they have changed the way we treat advanced Hodgkin lymphoma. This video was recorded at the EBMT 2018 Annual Meeting, held in Lisbon, Portugal.

More from Martin Hutchings

2:54
Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL
Martin Hutchings • 10 Dec 2023
3:58
Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRS
Martin Hutchings • 10 Dec 2023
Bispecific antibodies in NHL
Krish Patel et al. • 17 Oct 2023
1:32
Assessing the dynamics of CD8-expressing cells in patients with R/R LBCL treated with glofitamab
Martin Hutchings • 11 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals